+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 149 Pages
  • August 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5654093
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Drugs In Development, 2022, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 20, 4, 10, 3, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Post Menopausal Osteoporosis - Overview
  • Post Menopausal Osteoporosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Post Menopausal Osteoporosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
  • Post Menopausal Osteoporosis - Drug Profiles
  • Post Menopausal Osteoporosis - Dormant Projects
  • Post Menopausal Osteoporosis - Discontinued Products
  • Post Menopausal Osteoporosis - Product Development Milestones
  • Featured News & Press Releases
  • Jul 20, 2022: Henlius Denosumab Biosimilar HLX14 received clinical trial approval in Australia for the phase 3 MRCT
  • Jun 17, 2022: Voluntary announcement - First patient has been dosed in an international multicentre phase 3 clinical trial for a biosimilar of denosumab HLX14 (recombinant anti-RANKL human monoclonal antibody injection) for the treatment of postmenopausal osteoporosis in women with high fracture risks in Mainland China
  • Jun 08, 2022: Radius Health expands Non-US market footprint for TYMLOS
  • Jun 01, 2022: Radius Health update on Abaloparatide Transdermal System
  • Dec 23, 2021: Radius announces update on TYMLOS (abaloparatide) label
  • Dec 08, 2021: Radius announces results from the wearABLe trial evaluating abaloparatide transdermal system in postmenopausal women with osteoporosis
  • Oct 06, 2021: Entera Bio presents positive phase 2 6-month bone mineral density data for oral PTH formulation at Late Breaker ASBMR Conference Session
  • Sep 22, 2021: Radius Health announces TYMLOS label and business update
  • Sep 01, 2021: Entera Bio selected for late breaking oral presentation of phase 2 6-month osteoporosis data at ASBMR 2021 Annual Meeting
  • Jan 25, 2021: Luye Pharma LY06006 completed the last dosing for all subjects in phase III Clinical in China
  • Dec 14, 2020: Samsung Bioepis initiates phase 3 clinical trial for SB16, proposed biosimilar to Prolia (Denosumab)
  • Oct 23, 2020: Boan Biotech receives EU clinical trials application approval for Denosumab injection
  • Sep 09, 2020: Radius Health announces scientific presentations on abaloparatide at ASBMR 2020 Annual Meeting
  • Sep 08, 2020: Radius Health: Enrollment completed for Phase 3 wearABLe trial
  • Aug 20, 2020: Entera Bio announces interim data from phase 2 clinical trial of EB613 in osteoporosis and second quarter 2020 financial results
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Post Menopausal Osteoporosis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Companies, 2022 (Contd..1)
  • Products under Development by Companies, 2022 (Contd..2)
  • Products under Development by Companies, 2022 (Contd..3)
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Post Menopausal Osteoporosis - Dormant Projects, 2022
  • Post Menopausal Osteoporosis - Dormant Projects, 2022 (Contd..1)
  • Post Menopausal Osteoporosis - Discontinued Products, 2022
List of Figures
  • Number of Products under Development for Post Menopausal Osteoporosis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Ablynx NV
  • Addpharma Inc
  • Airsea (Taizhou) Pharmaceutical Ltd
  • AlphaMab Co Ltd
  • Alvotech SA
  • Amgen Inc
  • Aryogen Pharmed Co
  • Beijing Kangleweishi Biotechnology Co Ltd
  • Beijing Northland Biotech Co Ltd
  • Biocon Ltd
  • Celltrion Inc
  • Clayton Biotechnologies Inc
  • Clonz Biotech Pvt Ltd
  • CSPC Pharmaceutical Group Ltd
  • Eden Biologics Inc
  • Eli Lilly and Co
  • Entera Bio Ltd
  • Enteris BioPharma Inc
  • Enzene Biosciences Ltd
  • Epygen Biotech Pvt Ltd
  • Fresenius Kabi SwissBioSim GmbH
  • Gedeon Richter Plc
  • Genor BioPharma Co Ltd
  • Hualan Biological Engineering Inc
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu T-mab BioPharma Co Ltd
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • Mabxience Holding SL
  • Nano Intelligent Biomedical Engineering Corp
  • Nanomedic Inc
  • NeuClone Pty Ltd
  • Paras Biopharmaceuticals Finland Oy
  • Qilu Pharmaceutical Co Ltd
  • Reliance Life Sciences Pvt Ltd
  • Samsung Bioepis Co Ltd
  • Sandoz International GmbH
  • Shandong New Time Pharmaceutical Co Ltd
  • Shanghai Henlius Biotech Inc
  • Shanghai Mab Venture Biopharm Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Teva Pharmaceutical Industries Ltd
  • Uni-Bio Science Group Ltd
  • Wuxi Hebang Biotechnology Co Ltd